Background Donanemab (LY3002813) is an IgG1 antibody directed at an N-terminal
pyroglutamate of amyloid beta epitope that is present only in brain amyloid plaques …

Introduction This study explored the safety and tolerability features of donanemab
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …

Donanemab is an amyloid‐targeting therapy that resulted in robust amyloid plaque
reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the …

Background A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ)
peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being …

Importance Plasma biomarkers of Alzheimer disease may be useful as minimally invasive
pharmacodynamic measures of treatment outcomes. Objective To analyze the association of …

Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain …

Previous findings from the positron emission tomography (PET) substudy of the SCarlet
RoAD and Marguerite RoAD open-label extension (OLE) showed gantenerumab doses up …

Availability of safe and effective treatmentsfor Alzheimer disease is an urgent challenge
given the global shift toward an older population and increased risk of mild cognitive …

Importance β-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer
disease. Objective To perform post hoc analyses of amyloid reduction after donanemab …

Background We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully
human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor …